Sheila Kahyaoglu, Jefferies aerospace and defense analyst, joins CNBC's The Exchange to discuss why her firm increased the ...

Fintel reports that on January 7, 2025, Jefferies upgraded their outlook for Instil Bio (NasdaqCM:TIL) from Hold to Buy.

Jefferies analyst Daniel Fannon maintained a Buy rating on Goldman Sachs Group (GS – Research Report) today and set a price target of $667.00.

Key stocks recommended by Jefferies for 2025 include Mankind Pharma, JB Chemicals, and Sun Pharmaceutical Industries.

Jefferies downgraded Blue Star Ltd. to 'hold' from 'buy' after the stock rallied 140% in calendar year 2024. The stock is now ...

Zomato receives positive outlook from analysts, maintaining "Overweight" rating with target price of 355, despite recent ...

Jefferies believes aggressive moves by incumbents and entry of new players in the QC space can result in higher discounting ...

Investing.com-- Jefferies downgraded Indian food delivery firm Zomato Ltd (NS: ZOMT) on Monday, stating that the stock was likely to see a year of consolidation after strong gains in 2024 due to ...

The global brokerage firm revised the target lower, citing increasing competition as a threat to the online food aggregator’s ...

Over $7 trillion in assets are managed by its platforms, which organize investment data and monitor portfolios.

BRADENTON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (“First Watch” or the “Company”) (Nasdaq: FWRG), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced that Chris ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.